belantamab mafodotin-blmf for injection
for injection, for intravenous use Initial U.S. Approval: 2020
Blenrep (belantamab mafodotin-blmf) is a medication used for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody.
Facts about belantamab mafodotin-blmf for injection
Disease Indications-Multiple Myeloma
Medicine Approved By-European Medical Agency (EMA), Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “belantamab mafodotin-blmf for injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For belantamab mafodotin-blmf for injection
Approved accessible "belantamab mafodotin-blmf for injection"
Blenrep is a cancer medicine used to treat multiple myeloma (a cancer of the bone marrow). It is given to adults who have received at least four previous treatments and whose disease does not respond to treatment with at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody (types of cancer medicines), and whose cancer has worsened since receiving the last treatment.
Multiple myeloma is rare, and Blenrep was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 October 2017. Blenrep contains the active substance belantamab mafodotin.
How can 1 go about obtaining belantamab mafodotin-blmf for injection?
To access belantamab mafodotin-blmf for injection sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
BLENREP (belantamab mafodotin-blmf) for injection, for intravenous use Initial U.S. Approval: 2020
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Indian Pharma Network
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398